Transplant Diagnostics Market Benefits from Healthcare Digitization

The global transplant diagnostics market was valued at USD 6.39 billion in 2024 and is projected to reach USD 12.15 billion by 2033, expanding at a CAGR of 7.45% from 2025 to 2033. Market growth is primarily supported by the rising prevalence of genetic and chronic disorders, continuous advancements in genetic and molecular testing technologies, and increasing adoption of personalized medicine approaches in transplantation care.

Transplant diagnostics play a critical role in ensuring donor–recipient compatibility, minimizing organ rejection risks, and improving post-transplant outcomes. Growing awareness among healthcare providers and patients regarding the importance of precise diagnostic testing continues to accelerate market demand globally.

Key Market Trends & Insights

• North America accounted for the largest global revenue share of 32.52% in 2024
• The U.S. led the North American market with the highest revenue contribution in 2024
• By test type, the molecular assays segment dominated with a revenue share of 41.37% in 2024
• By application, the diagnostic segment held the largest share at 70.93% in 2024
• By transplant area, solid organ transplantation led the market with a 45.63% revenue share in 2024

Market Size and CAGR

• 2024 Market Size: USD 6.39 Billion
• 2033 Projected Market Size: USD 12.15 Billion
• CAGR (2025–2033): 7.45%
• Largest Regional Market (2024): North America
• Fastest-Growing Region: Asia Pacific

In October 2025, UBC enzyme technology introduced the first human test aimed at enabling universal donor organs for transplantation. The technology successfully converted a kidney to universal blood type O, representing a major breakthrough in reducing donor-recipient incompatibility. The transplanted kidney functioned normally for two days without signs of hyperacute rejection. Although some blood-type markers reappeared by the third day, the immune response was moderate and significantly less severe than typical mismatched transplants. Researchers also observed early indicators of immune tolerance development.

Such innovations highlight the growing importance of advanced transplant diagnostics in enabling safer, faster, and more compatible organ transplants.

The expanding aging population, increasing prevalence of chronic diseases, and advancements in transplantation techniques continue to propel market growth. According to the World Health Organization, in 2020, the global population aged 60 and above surpassed children under the age of five. Between 2015 and 2050, the proportion of individuals over 60 years is expected to nearly double from 12% to 22%, with 80% residing in low- and middle-income countries by 2050.

As chronic conditions such as kidney failure, heart disease, and liver disorders rise, the demand for organ transplantation as a life-saving intervention increases correspondingly. This trend reinforces the need for accurate transplant diagnostics to enhance compatibility assessment, reduce rejection risks, and improve long-term transplant success rates.

The transplant diagnostics industry continues to evolve through ongoing innovation in diagnostic platforms and medical devices. Emerging technologies such as AI-powered diagnostics, robotic-assisted transplantation, and 3D bioprinting of organs are transforming organ selection, surgical precision, and patient outcomes. Hospitals and specialized transplant centers remain the primary adopters of these advanced diagnostic solutions.

Order a free sample PDF of the Transplant Diagnostics Market Intelligence Study, published by Grand View Research.

Key Transplant Diagnostics Company Insights

The market is characterized by the presence of several established players focused on product innovation, geographic expansion, and strategic partnerships to strengthen their market positions.

Leading Transplant Diagnostics Companies:

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Hoffmann-La Roche Ltd
• Abbott
• QIAGEN
• Bruker
• BD (Becton, Dickinson and Company)
• Werfen (Immucor, Inc.)
• Bio-Rad Laboratories, Inc.
• Omixon Inc.

Conclusion

The global transplant diagnostics market is poised for sustained growth through 2033, driven by rising transplant volumes, an aging population, and rapid advancements in molecular and genetic diagnostic technologies. Continuous innovation in diagnostics, combined with increasing awareness of donor–recipient compatibility, is enhancing transplantation success rates worldwide. As healthcare systems prioritize precision medicine and advanced transplant solutions, transplant diagnostics will remain a critical enabler of improved patient outcomes and long-term graft survival.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.